Exploring FDA-Approved Frontiers: Insights into Natural and Engineered Peptide Analogues in the GLP-1, GIP, GHRH, CCK, ACTH, and α-MSH Realms

Othman Al Musaimi

Open source

DOI
10.3390/biom14030264
Published
02
Container
Biomolecules
Publisher
Not recorded
Open access
yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3390/biom14030264,
  title = {Exploring FDA-Approved Frontiers: Insights into Natural and Engineered Peptide Analogues in the GLP-1, GIP, GHRH, CCK, ACTH, and α-MSH Realms},
  author = {Othman Al Musaimi},
  year = {2024},
  journal = {Biomolecules},
  doi = {10.3390/biom14030264},
  url = {https://doi.org/10.3390/biom14030264}
}

RIS

TY  - JOUR
TI  - Exploring FDA-Approved Frontiers: Insights into Natural and Engineered Peptide Analogues in the GLP-1, GIP, GHRH, CCK, ACTH, and α-MSH Realms
AU  - Othman Al Musaimi
PY  - 2024
JO  - Biomolecules
DO  - 10.3390/biom14030264
UR  - https://doi.org/10.3390/biom14030264
ER  - 

APA

Musaimi, O. A. (2024). Exploring FDA-Approved Frontiers: Insights into Natural and Engineered Peptide Analogues in the GLP-1, GIP, GHRH, CCK, ACTH, and α-MSH Realms. Biomolecules. https://doi.org/10.3390/biom14030264

Source records